PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22056254-2	2012	Here we determine the effect of the tumor suppressor protein, p53, on trafficking (64)Cu to tumor cell nuclei from DOTA vs. CB-TE2A-conjugated agonist Y3-TATE and the antagonist (64)Cu-CB-TE2A-sst2-ANT in cell lines that are positive or negative for p53.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	115-119	tumor protein p53	Homo sapiens	62-65	
17938576-7	2008	However, nuclear localization of (64)Cu-DOTA-cetuximab showed increased uptake in the nuclei of HCT 116 +/+ cells as early as 4 h. These data demonstrate that (64)Cu is delivered to tumor cell nuclei in a p53 positive cell line in significantly greater amounts than in p53 negative cells by both non-specific and receptor-mediated uptake mechanisms.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	37-44	tumor protein p53	Homo sapiens	205-208	
17938576-7	2008	However, nuclear localization of (64)Cu-DOTA-cetuximab showed increased uptake in the nuclei of HCT 116 +/+ cells as early as 4 h. These data demonstrate that (64)Cu is delivered to tumor cell nuclei in a p53 positive cell line in significantly greater amounts than in p53 negative cells by both non-specific and receptor-mediated uptake mechanisms.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	37-44	tumor protein p53	Homo sapiens	269-272